Moreover, since it is through the host ACE2 receptor that SARS-CoV-2 infection begins, it was interesting to find that, in El-Shennawy et al.’s [72] research, the circulant small EVs of plasma samples of COVID-19 patients have more significant expression of ACE2 (ExoACE2) when compared to EVs of plasma samples of individuals with no SARS-CoV-2 infection. The gene discussed is ACE2; the disease is COVID-19.